论文部分内容阅读
目的探讨PDT(吡柔比星、地塞米松加沙利度胺)方案与VAD方案(长春新碱、阿霉素加地塞米松)治疗多发性骨髓瘤(MM)患者的疗效及不良反应。方法采用PDT方案治疗多发性骨髓瘤患者18例,与采用VAD方案治疗的20例患者进行对比,观察疗效及不良反应。结果 PDT组总有效率66.7%,VAD组总有效率65.0%,两组比较,差异无统计学意义(P>0.05)。PDT组不良反应小于VAD组,差异有统计学意义(P<0.05)。结论 PDT方案是治疗多发性骨髓瘤的可行方案之一,治疗效果较佳,且心脏毒性及周围神经炎发生率明显降低。
Objective To investigate the efficacy and side effects of PDT (pirarubicin, dexamethasone plus tegaserod) and VAD (vincristine and doxorubicin plus dexamethasone) in patients with multiple myeloma (MM). Methods 18 patients with multiple myeloma treated with PDT regimen were compared with 20 patients treated with VAD regimen to observe the curative effect and adverse reactions. Results The total effective rate was 66.7% in PDT group and 65.0% in VAD group. There was no significant difference between the two groups (P> 0.05). Adverse reactions in PDT group were less than those in VAD group, with significant difference (P <0.05). Conclusions The PDT regimen is one of the feasible options for the treatment of multiple myeloma. The therapeutic effect is better, and the incidence of cardiotoxicity and peripheral neuropathy is significantly lower.